BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine
August 15 2016 - 8:00AM
Business Wire
New Patents Supplement Existing Portfolio of
More Than 700 Patents and Patent Applications Owned or Licensed by
BioTime Family of Companies Worldwide
BioTime, Inc. (NYSE MKT:BTX) today announced the issuance of 31
new patents between July 3, 2015 and August 3, 2016 that are owned
by or licensed to BioTime, or its family of companies. The new
patents add to the over 700 issued and pending patents worldwide in
the collective portfolio and further strengthen the Company and its
affiliates’ IP position in the field of regenerative medicine. The
new patents include nine new U.S. patents, as well as 22 additional
patents issued in Australia, Canada, China, India, Israel, and
Japan.
“Patents are a key asset for biotechnology companies, especially
in cases of emerging platform technologies such as pluripotent stem
cell-based regenerative medicine,” said Michael D. West, Ph.D.,
BioTime’s Co-Chief Executive Officer. “Our pluripotent stem cell
platform allows for the potential scalable manufacture of every
cell type of the human body for a wide array of potential
therapeutic and diagnostic applications. We plan to utilize these
new patents to protect our core proprietary products in current and
future development, as well as to attract new corporate alliances
for the development of new products and applications.”
Select examples of new patents issued in the United States
include:
- United States patent 9074181 –
Claims methods for the culture of undifferentiated stem cells while
in suspension as opposed to attached to the surface of a vessel.
Such suspension culture enables full use of the three-dimensional
space of the culture vessel and provides a rapid, efficient way of
expanding undifferentiated stem cells, which may substantially
reduce the cost of producing such cells in commercial
quantities.
- United States patent 9085756 –
Claims methods of screening for factors that differentiate primate
pluripotent stem cells into pancreatic islet cells. These methods
are useful for the manufacture of pancreatic islet cells for drug
discovery and transplantation in humans for the treatment of
diabetes.
- United States patents 9404085 and
9115343 – Claim culture media for differentiating stem cells to
cardiac muscle cells, and methods for screening factors that induce
differentiation of stem cells to cardiac muscle cells,
respectively. The patents may have future uses in the manufacture
of cardiac muscle cells from pluripotent stem cells.
- United States patent 9175263 –
Claims peptide compositions that bind to and target a wide array of
human progenitor cell lines. This patent is useful in the
identification, screening, and purification of various cell lines,
and potentially other diverse uses in preparing certain human cell
types for use in research and therapy.
- United States patents 9243229 and
9238794 – Claim cultures of cardiac muscle cells and
oligodendrocyte progenitor cells on cell culture surfaces
containing certain specific polymers, respectively. These patents
allow culturing of the claimed cell types in an environment free of
animal-derived components and are therefore potentially useful for
future therapeutic applications such as transplantation or drug
testing.
Additional patents issued in the same time period include:
- United States patents 9074182, and
9115360
- Australia patents 2009209157,
2009209167, 2012203350, 2009228215, 2011218041 and 2012225784
- Canada patents 2692325, 2350210,
2453438, 2573437, 2569485, 2549295 and 2489712
- China patents ZL200910152133.X,
ZL201010528128.7 and 201080041322.0
- India patent 269782
- Israel patent 203575
- Japan patents 5770213, 5792428, 5917429
and 5926240
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what we believe to be the world’s premier collection of pluripotent
cell assets. The foundation of our core therapeutic technology
platform is pluripotent cells that are capable of becoming any of
the cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient
needs, including various age-related degenerative diseases and
degenerative conditions for which there presently are no cures.
Unlike pharmaceuticals that require a molecular target, therapeutic
strategies based on the use of pluripotent cells are generally
aimed at regenerating or replacing affected cells and tissues, and
therefore may have broader applicability than pharmaceutical
products.
In addition to the development of therapeutics, BioTime’s
research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic
market opportunities such as cancer diagnostics, drug development
and cell research products, and mobile health software
applications.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime and
its subsidiaries, particularly those mentioned in the cautionary
statements found in BioTime's Securities and Exchange Commission
filings. BioTime disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160815005444/en/
BioTime, Inc.Dan L. Lawrence,
510-775-0510dlawrence@biotimeinc.comorInvestor Contact:EVC Group,
Inc.Michael Polyviou, 646-445-4800mpolyviou@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2024 to May 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2023 to May 2024